14 min. Read
10.02.20

Five investors talk digital therapeutics: Red flags, starting up, and COVID–19

At the virtual DTx East conference in September, five active investors with a focus on digital therapeutics discussed the market. Here are four of the topics they dug into:

  • What they look for in potential investment targets
  • Red flags when evaluating a digital therapeutic startup
  • What startups should look for in investors
  • How COVID--19 has just been a speedbump for some and created tailwinds for others
  • And more...

Here are the panelists and notes from their self-introductions:

Caleb Winder, Managing Director, MemorialCare Innovation Fund

We are focused on investing in healthcare companies across the US in early Series B or later.

Chihiro Hosoya Head of Venture Management & Business Development, Rx+ Business Accelerator Astellas Pharma

Astellas is a pharmaceutical company based in Japan but we operate globally. My scope includes both digital and devices, so we are super interested in

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
Better Therapeutics shuts down. Mahana-Cara Care
3.18.24
5 min. Read
HCPCS and CPT decisions. Akili results. Click trials
3.08.24
7 min. Read
De Novo: Samsung Galaxy Watch gets OTC sleep apnea detection
2.16.24
7 min. Read
Facebook’s RCT for AI bot Zenny. More trials
1.30.24
7 min. Read
FDA de novo for Google smartphone thermometer.
1.05.24
6 min. Read
PDT-to-virtual-clinic trend continues. HCPCS tweaks.
12.15.23
8 min. Read
Mahana Tinnitus. New CPT hopefuls. Better cuts salaries
12.01.23
6 min. Read
CMS weighs HCPCS for Natural Cycles, Leva, and Tyto. Plus: Akili Q3 results.
11.16.23
8 min. Read
metaMe Health seeks buyer by year-end. CMS offers up digital therapeutics nothingburger
11.06.23
6 min. Read
PDT Pipeline changes. Kinsa shuts down. Trials
10.27.23
5 min. Read
  • First
  • Previous
  • 1 of 20
  • Next
  • Last